37results about How to "Reduce collagen content" patented technology

The invention pertains to the field of traditional Chinese medicines and relates to a medicine for treating chronic liver diseases. The invention adopts the active ingredients or components in cordyceps polysaccharide, amygdalin and gypenosides with a specific mixture ratio to compose a drug composite with ideal therapeutic effects of resisting hepatic fibrosis and liver injury. By the model tests of classic animals and verification, results confirm that the medicine can remarkably reduce the collagen concentration of the liver tissues of rat models, lighten the degrees of hepatic fibrosis and liver injury and improve the effects of resisting hepatic fibrosis, effectively prevent the development of hepatic fibrosis and promote the reversion of hepatic fibrosis. The effects are better than that of individually using each ingredient; the medicine can be used for treating and preventing various diseases, such as chronic hepatitis, hepatic fibrosis, hepatocirrhosis and the like. The medicine can be prepared into oral solid preparations, such as granules, tablets, capsules and the like.

Described herein are compositions comprising shortened fibers of poly-N-acetylglucosamine and / or a derivative thereof (“sNAG nanofibers”) and the use of such compositions in the treatment of various diseases, in particular, diseases associated with decreased tensile strength of tissue, decreased elasticity of tissue, increased collagen content or abnormal collagen content in tissue, abnormal alignment of collagen in tissue, and / or increased myofibroblast content in tissue.

The invention discloses a human skin tissue endogenous polypeptide PDHPS1 and an application thereof. The amino acid sequence of the human skin tissue endogenous polypeptide PDHPS1 is shown in SEQ IDNO.1. The polypeptide PDHPS1 inhibits the propagation of a scar dermal fibroblast, inhibits the expression of mRNA of collagen genes COL1A1 and COL1A2 in the scar dermal fibroblast, and obviously reduces the protein expression of a main marker alpha-SMA of a myofibroblast in the scar dermal fibroblast. The human skin tissue endogenous polypeptide PDHPS1 can be used to prepare a drug or agent whichcan inhibit the propagation of the scar dermal fibroblast, reduce the collagen content and reduce the amount of the myofibroblast, and provides a new target spot for inhibiting the scar hypertrophy.

A Chinese medicine for treating the slow-transmission constipation is prepared from 13 Chinese-medicinal materials including tangerine peel, astragalus root, Chinese angelica root, rehmannia root, etc through proportional mixing, distilling, extracting, concentrating, drying and loading in capsules.

The invention discloses a traditional Chinese medicine composition used for treating chronic liver diseases. The composition is composed of the raw medicine materials of, by weight, 6-18 parts of common burreed tuber, 6-18 parts of blue turmeric rhizome, and 9-30 parts of turtle shell. According to the invention, blood-circulation-activating, stasis-removing, hard-mass-softening, and stagnation-eliminating traditional Chinese medicines are used for producing the medicine composition with functions of hepatic fibrosis inhibiting and hepatic damage inhibiting. Classic animal model experiments and validation are carried out. As a result, the traditional Chinese medicine composition provided by the invention assists in substantially reducing model rat liver tissue collagen content, reducing hepatic fibrosis degree and hepatic damage degree, effectively inhibiting hepatic fibrosis development, and promoting hepatic fibrosis reversing. The composition provided by the invention can be used for treating and preventing various diseases such as chronic hepatitis, liver fibrosis, cirrhosis, liver tumor, and the like. The medicine can be prepared into oral solid preparations such as tablets, granules, capsules, and the like.

The invention discloses a human adipose stem cell secreted polypeptide ADSCP2 and its application. A human adipose stem cell secreted polypeptide ADSCP2, the amino acid sequence of which is shown in SEQ ID NO.1. The polypeptide ADSCP2 can inhibit the mRNA expression of collagen genes COL1A1, COL1A2, and COL3A1 in human scar dermal fibroblasts, and significantly reduce the mRNA expression of the main myofibroblast marker ACTA2 in human scar dermal fibroblasts. The human adipose stem cell secreted polypeptide ADSCP2 can be used to prepare drugs or reagents for reducing the collagen content of fibroblasts in scar dermis and the amount of myofibroblasts, providing a new target for inhibiting scar hyperplasia.